RT Journal Article
SR Electronic
T1 A 6-mRNA host response whole-blood classifier trained using patients with non-COVID-19 viral infections accurately predicts severity of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.07.20230235
DO 10.1101/2020.12.07.20230235
A1 Buturovic, Ljubomir
A1 Zheng, Hong
A1 Tang, Benjamin
A1 Lai, Kevin
A1 Kuan, Win Sen
A1 Gillett, Mark
A1 Santram, Rahul
A1 Shojaei, Maryam
A1 Almansa, Raquel
A1 Ángel Nieto, Jose
A1 Muñoz, Sonsoles
A1 Herrero, Carmen
A1 Antonakos, Nikolaos
A1 Koufargyris, Panayiotis
A1 Kontogiorgi, Marina
A1 Damoraki, Georgia
A1 Liesenfeld, Oliver
A1 Wacker, James
A1 Midic, Uros
A1 Luethy, Roland
A1 Rawling, David
A1 Remmel, Melissa
A1 Coyle, Sabrina
A1 Liu, Yiran
A1 Rao, Aditya M
A1 Dermadi, Denis
A1 Toh, Jiaying
A1 Jones, Lara Murphy
A1 Donato, Michele
A1 Khatri, Purvesh
A1 Giamarellos-Bourboulis, Evangelos J.
A1 Sweeney, Timothy E
YR 2020
UL http://medrxiv.org/content/early/2020/12/08/2020.12.07.20230235.abstract
AB Background While major progress has been made to establish diagnostic tools for the identification of SARS-CoV-2 infection, determining the severity of COVID-19 remains an unmet medical need. There is a limited availability of hospital resources in this or any pandemic, and appropriately gauging severity would allow for some patients to safely recover in home quarantine, while ensuring that sicker patients get needed care.Methods We here developed a blood-based generalizable host-gene-expression-based classifier for the severity of viral infections and validated it in multiple viral infection settings including COVID-19. We used training data (N=705) from 21 retrospective transcriptomic clinical studies of influenza and other viral illnesses looking at a preselected panel of host immune mRNAs.Results We selected 6 host mRNAs and trained a logistic regression classifier with a training cross-validation AUROC of 0.90 for predicting 30-day mortality in viral illnesses. Next, in 1,417 samples across 21 independent retrospective validation cohorts the locked 6-mRNA classifier had an AUROC of 0.91 for discriminating patients with severe vs. non-severe infection. Next, in an independent cohort of prospectively enrolled patients with confirmed COVID-19 (N=97) in Athens, Greece, the 6-mRNA locked classifier had an AUROC of 0.89 for identifying patients with severe respiratory failure or 30-day mortality. Finally, we developed an isothermal qRT-LAMP (loop-mediated isothermal gene expression) assay for the 6-mRNA panel to facilitate implementation as a rapid assay.Conclusions With further study, the classifier could assist in the risk assessment of patients with confirmed SARS-CoV-2 infection and COVID-19 to determine severity and level of care, thereby improving patient management and healthcare burden.Competing Interest StatementLB, OL, JW, UM, RL, DR, MR, SC, and TES are employees of, and stockholders in, Inflammatix, Inc, which is developing the 6-mRNA score into a commercial assay, CoVerityTM. PK is a shareholder and a consultant to Inflammatix, Inc. EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMerieux Inc, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors declare no competing interests. Clinical TrialEudraCT 2020-001039-29Funding StatementThis study was funded by Inflammatix Inc. No external funding was received Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:COVID-19 blood samples were collected between March and April 2020. The studies were conducted following approvals for the collection of biomaterial for transcriptomic analysis for patients with lower respiratory tract infections provided by the Ethics Committees of the participating hospitals. The studies were conducted under the 23/12.08.2019 approval of the Ethics Committee of Sotiria Athens General Hospital; and the 26.02.2019 approval of the Ethics Committee of ATTIKON University General Hospital. Written informed consent was provided by patients or by first-degree relatives in case of patients unable to consent. For Australia/WIMR study, the written consent is provided by all patients or by first-degree relatives in case of patients unable to consent. The study was approved by the human research ethics committee of the Nepean Blue Mountains Area Health Services. For PREVISE study, the IRB was approved by COMITE DE ETICA DE LA INVESTIGACION CON MEDICAMENTOS DEL AREA DE SALUD DE SALAMANCA, Paseo de San Vicente, 58-18, 237007 Salamanca, Spain For healthy commercial controls, blood RNA tubes were prospectively collected from healthy controls (HC) through a commercial vendor (BioIVT) under IRB approval (Western IRB #2016165) using informed consent. Stanford ICU databank and PROMPT studies have previously been published and provided IRB details.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe public cohorts are available under their respective study IDs. The Stanford ICU Databank study is available at https://doi.org/10.1038/s41467-020-14975-w. The COVID-19 NanoString data are available upon reasonable request from the authors. https://doi.org/10.1038/s41467-020-14975-w